Quantum-Si incorporated QSI
As ofNov 19, 2026, 2:13 PM EST
- YTD
- -2.27%
- 1 year
- -16.02%
5D -0.11 (-9.17%)
- Market cap
- 237.32M
- Revenue (ttm)
- 2.27M
- EPS (ttm)
- -0.38
- Shares out
- 155.96M
- Forward P/E
- -1.66
- YTD return
- -2.27%
- 1-year return
- -16.02%
- 50-day average
- 1.08
- Volume
- 2.68M
- Avg volume
- 6.84M
- Open
- 1.10
- Previous close
- 1.07
- Day's range
- 1.07 – 1.13
- 52-week range
- 0.69 – 1.81
- Beta
- 2.93
- Price target
- 3.25 (+202.3%)
Key statistics
- 200-day average
- 1.26
- Enterprise value
- 3.01M
- Price / sales
- 90.16
- Price / book
- 0.89
- Revenue growth
- 252.90%
- Total cash
- 196.34M
- Total debt
- 13.82M
- Return on equity
- -35.79%
- Short % of float
- 10.52%
Fundamental scorecard
4 of 25 checks passed on QSI’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.21 | -0.18 | +0.03 | +14.29% |
| Aug 7, 2024 | Jun 1, 2024 | -0.21 | -0.16 | +0.05 | +23.81% |
| Aug 7, 2024 | Jun 1, 2024 | -0.21 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.23 | -0.14 | +0.09 | +39.13% |
| May 9, 2024 | Mar 1, 2024 | -0.23 | — | — | — |
| Feb 29, 2024 | Dec 1, 2023 | -0.16 | -0.16 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 21, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 13, 2024 | Canaccord Genuity | main | Hold | Hold |
| Nov 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 1, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Dec 8, 2023 | HC Wainwright & Co. | init | — | Buy |
About Quantum-Si incorporated
Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; Proteus, transforming proteomic research; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company has a collaboration with SkyWaterTechnology for the development of consumable for Proteus, that will enable simultaneous protein sequencing. Quantum-Si incorporated was founded in 2013 is headquartered in Branford, Connecticut.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- quantum-si.com
News
Quantum-Si Announces Detection Of All 20 Naturally Occurring Amino Acids In Its Proteus Development Program, Reaching Year-End 2026 Goal Ahead Of Schedule
Quantum-Si Achieves Historic Milestone in Protein Sequencing with Single-Molecule Detection of All 20 Amino Acids on Proteus™
QUANTUM X AND EVEREST CLOUD PARTNER TO BRING QUANTUM AND AI COMPUTE TO SIX SOUTH ASIAN MARKETS
Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Quantum-Si Q3 2026 Earnings Call Transcript Quantum-Si Affirms FY2026 Sales Guidance of $1.000M vs $1.132M Est
Your note
Sign in to keep a note on QSI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BENNETT TODD C | Officer | Stock Award(Grant) | Sep 16, 2024 | 510,152 |
| DOWDY PAULA | Director | Stock Award(Grant) | Mar 21, 2024 | 159,217 |
| HAWKINS JEFFREY ALAN | Chief Executive Officer | Purchase | Aug 8, 2024 | 1,003,760 |
| JAFRI AMIR | Director | Stock Award(Grant) | Sep 24, 2023 | 115,942 |
| JOHNSTON GRACE | Officer | Sale | Jun 23, 2024 | 295,940 |
| KENNY JOHN P | Director | Stock Award(Grant) | May 21, 2023 | 114,285 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK Investment Management, LLC | 9.65% | 11,842,609 | 15.51M | Sep 29, 2024 |
| Sumitomo Mitsui Trust Holdings, Inc. | 6.15% | 7,547,912 | 9.89M | Sep 29, 2024 |
| Nikko Asset Management Americas, Inc. | 6.13% | 7,527,912 | 9.86M | Sep 29, 2024 |
| Blackrock Inc. | 5.62% | 6,900,127 | 9.04M | Sep 29, 2024 |
| Vanguard Group Inc | 4.10% | 5,037,258 | 6.60M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.89% | 2,316,921 | 3.04M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Tr-ARK Genomic Revolution ETF | 9.36% | 11,497,793 | 15.06M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.46% | 3,017,586 | 3.95M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.99% | 2,441,722 | 3.20M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.04% | 1,276,774 | 1.67M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.84% | 1,027,584 | 1.35M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.83% | 1,023,701 | 1.34M | Oct 30, 2024 |
